' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Epilepsy-related stigma in European people with epilepsy: Correlations with health system performance and overall quality of life.
Brigo, F; Igwe, SC; Ausserer, H; Tezzon, F; Nardone, R; Otte, WM;
Epilepsy Behav. 2015; 42: 18-21.
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Nardone Raffaele

Abstract

AHA is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60-80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guiding IST intensity, but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR, defined as no active bleeding, FVIII restored >50 IU/dl, hemostatic treatment stopped >24 h) was achieved by 83% of patients after a median of 31 days (range 7-362). Patients with baseline FVIII <1 IU/dl achieved PR less often and later (77%, 43 days) than patients with ≥1 IU/dl (89%, 24 days). After adjustment for other baseline characteristics, low FVIII remained associated with a lower rate of PR (hazard ratio 0.52, 95% confidence interval 0.33-0.81, p<0.01). In contrast, PR achieved on steroids alone within ≤21 days was more common in patients with FVIII ≥1 IU/dl and inhibitor concentration <20 BU/ml (odds ratio 11.2, p<0.0001). Low FVIII was also associated with a lower rate of complete remission and decreased survival. In conclusion, presenting FVIII and inhibitor concentration are potentially useful to tailor IST in AHA. Copyright © 2014 American Society of Hematology.


Find related publications in this database (Keywords)

Epilepsy
Health expenditure
Health system performance
Stigma